Tec-Dara combination offers improvement over standard second-line therapies for relapsed, refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease…

Continue Reading

News Source: medicalxpress.com